| Year |
Citation |
Score |
| 2020 |
Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, ... ... Febbo P, et al. The DNA methylation landscape of advanced prostate cancer. Nature Genetics. PMID 32661416 DOI: 10.1038/S41588-020-0648-8 |
0.388 |
|
| 2018 |
Canfield S, Kemeter MJ, Febbo PG, Hornberger J. Balancing Confounding and Generalizability Using Observational, Real-world Data: 17-gene Genomic Prostate Score Assay Effect on Active Surveillance. Reviews in Urology. 20: 69-76. PMID 30288143 DOI: 10.3909/Riu0799 |
0.406 |
|
| 2018 |
Magi-Galluzzi C, Isharwal S, Falzarano SM, Tsiatis A, Dee A, Maddala T, Knezevic D, Febbo PG, Lawrence J, Klein EA. The 17-gene Genomic Prostate Score Assay Predicts Outcome after Radical Prostatectomy Independent of PTEN Status. Urology. PMID 30142405 DOI: 10.1016/J.Urology.2018.07.018 |
0.563 |
|
| 2018 |
Rini BI, Escudier B, Martini JF, Magheli A, Svedman C, Lopatin M, Knezevic D, Goddard AD, Febbo PG, Li R, Lin X, Valota O, Staehler M, Motzer RJ, Ravaud A. Validation of the 16-Gene Recurrence Score in patients with locoregional, high-risk renal cell carcinoma from a phase 3 trial of adjuvant sunitinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29773662 DOI: 10.1158/1078-0432.Ccr-18-0323 |
0.304 |
|
| 2018 |
Salmasi A, Said J, Shindel AW, Khoshnoodi P, Felker ER, Sisk AE, Grogan T, McCullough D, Bennett J, Bailey H, Lawrence HJ, Elashoff DA, Marks LS, Raman SS, Febbo PG, et al. A 17-gene Genomic Prostate Score assay provides independent information on adverse pathology in the setting of combined mpMRI fusion-targeted and systematic prostate biopsy. The Journal of Urology. PMID 29524506 DOI: 10.1016/J.Juro.2018.03.004 |
0.567 |
|
| 2018 |
Lynch JA, Rothney MP, Salup RR, Ercole CE, Mathur SC, Duchene DA, Basler JW, Hernandez J, Liss MA, Porter MP, Wright JL, Risk MC, Garzotto M, Efimova O, Barrett L, ... ... Febbo PG, et al. Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assay. The American Journal of Managed Care. 24: S4-S10. PMID 29337486 |
0.466 |
|
| 2018 |
Shore N, Eure G, Saltzstein D, Bennett J, Lu R, Febbo P, Denes B. Mp35-14 A 17-Gene Assay Drives High Active Surveillance Persistence In Clinically Low-Risk Prostate Cancer: 1 Year Results From A 1,200 Patient Prospective Observational Trial The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1127 |
0.525 |
|
| 2018 |
Katz A, Loman C, Lu R, Febbo P, Denes B. Mp35-07 The 17-Gene Rt-Pcr Prostate Assay: Clinical Experience In 29,000 Patients With Clinically Low-Risk Prostate Cancer The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1120 |
0.565 |
|
| 2017 |
Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg MR, Carroll PR. Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa). Plos One. 12: e0185535. PMID 29016610 DOI: 10.1371/Journal.Pone.0185535 |
0.581 |
|
| 2017 |
Van Den Eeden SK, Lu R, Zhang N, Quesenberry CP, Shan J, Han JS, Tsiatis AC, Leimpeter AD, Lawrence HJ, Febbo PG, Presti JC. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease. European Urology. PMID 28988753 DOI: 10.1016/J.Eururo.2017.09.013 |
0.588 |
|
| 2017 |
Hughes KS, Ambinder EP, Hess GP, Yu PP, Bernstam EV, Routbort MJ, Clemenceau JR, Hamm JT, Febbo PG, Domchek SM, Chen JL, Warner JL. Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017741744. PMID 28737972 DOI: 10.1200/Jco.2017.74.1744 |
0.314 |
|
| 2017 |
Eure G, Germany R, Given R, Lu R, Shindel AW, Rothney M, Glowacki R, Henderson J, Richardson T, Goldfischer E, Febbo PG, Denes B. Use of a 17-gene prognostic assay in contemporary urologic practice: results of an interim analysis in an observational cohort. Urology. PMID 28454985 DOI: 10.1016/J.Urology.2017.02.052 |
0.535 |
|
| 2017 |
Lynch JA, Rothney M, Salup R, Ercole CE, Mathur S, Duchene D, Basler JW, Hernandez J, Liss MA, Porter MP, Wright JL, Risk MC, Efimova O, Denes BS, Febbo PG, et al. Treatment patterns after the use of the 17-gene Genomic Prostate Score assay in Veterans newly diagnosed with clinically low-risk prostate cancer. Journal of Clinical Oncology. 35: 54-54. DOI: 10.1200/Jco.2017.35.6_Suppl.54 |
0.549 |
|
| 2017 |
VanDenEeden SK, Zhang N, Quesenberry CP, Han JS, Leimpeter AD, Shan J, Tsiatis AC, Lawrence HJ, Febbo PG, Presti JC. Validation of a 17-Gene Genomic Prostate Score (GPS) as a predictor of biochemical recurrence (BCR) in men with prostate cancer treated with radical prostatectomy (RP) in a community setting. Journal of Clinical Oncology. 35: 41-41. DOI: 10.1200/Jco.2017.35.6_Suppl.41 |
0.539 |
|
| 2017 |
Shore ND, Richardson T, Rosenberg S, Goldfischer E, Lu R, Shindel AW, Bennett J, Karsh LI, Korman H, Febbo PG, Denes BS. Prospective study of a 17-GENE RT-PCR-based assay for prediction of high risk pathology at radical prostatectomy. Journal of Clinical Oncology. 35: 36-36. DOI: 10.1200/Jco.2017.35.6_Suppl.36 |
0.518 |
|
| 2017 |
Febbo PG, Crager M, Burke E, Lawrence HJ, Cullen J, Klein EA. Association of risk of clinical recurrence (CR) and prostate cancer death (PCD) with a 17-gene genomic prostate score (GPS) value <20. Journal of Clinical Oncology. 35: 5074-5074. DOI: 10.1200/Jco.2017.35.15_Suppl.5074 |
0.57 |
|
| 2017 |
Salmasi A, Said JW, Raman S, Shindel AW, McCullough D, Bailey H, Rothney M, Marks LS, Febbo PG, Reiter RE. A 17-gene panel for prediction of adverse surgical pathology in the setting of MRI-guided prostate biopsy. Journal of Clinical Oncology. 35: 5063-5063. DOI: 10.1200/Jco.2017.35.15_Suppl.5063 |
0.543 |
|
| 2017 |
Van Den Eeden S, Zhang N, Shan J, Quesenberry C, Han J, Tsiatis A, Lu R, Lawrence J, Febbo P, Presti J. Clinical validation of a 17-gene genomic prostate score (GPS) assay as a predictor of distant metastases in men with prostate cancer (PCa) treated with radical prostatectomy (RP) in a community setting European Urology Supplements. 16: e618-e619. DOI: 10.1016/S1569-9056(17)30416-5 |
0.574 |
|
| 2017 |
Eggener S, Richardson T, Rosenberg S, Goldfischer E, Lu R, Shindel A, Bennett J, Karsh L, Korman H, Febbo P, Denes B. Mp28-01 A 17-Gene Panel For Prediction Of Adverse Pathology At Radical Prostatectomy: Prospective Validation The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.814 |
0.331 |
|
| 2017 |
Van Den Eeden S, Zhang N, Shan J, Quesenberry C, Han J, Tsiatis A, Lu R, Lawrence J, Febbo P, Presti J. MP20-05 A DIAGNOSTIC BIOPSY-BASED GENOMIC PROSTATE SCORE AS AN INDEPENDENT PREDICTOR OF PROSTATE CANCER DEATH AND METASTASIS IN MEN WITH LOCALIZED PROSTATE CANCER Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.637 |
0.579 |
|
| 2017 |
Lynch J, Rothney M, Salup R, Ercole C, Mathur S, Duchene D, Basler J, Hernandez J, Liss M, Porter M, Wright JL, Risk M, Garzotto M, Efimova O, Kemeter M, ... ... Febbo P, et al. Mp86-16 A Multi-Center Analysis Of Prostate Cancer (Pca) Treatment Among Veterans Following Introduction Of The 17-Gene Genomic Prostate Score (Gps) Assay The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2699 |
0.579 |
|
| 2016 |
Albala D, Kemeter MJ, Febbo PG, Lu R, John V, Stoy D, Denes B, McCall M, Shindel AW, Dubeck F. Health Economic Impact and Prospective Clinical Utility of Oncotype DX® Genomic Prostate Score. Reviews in Urology. 18: 123-132. PMID 27833462 DOI: 10.3909/Riu0725 |
0.532 |
|
| 2016 |
Magi-Galluzzi C, Maddala T, Falzarano SM, Cherbavaz DB, Zhang N, Knezevic D, Febbo PG, Lee M, Lawrence HJ, Klein EA. Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect. Oncotarget. PMID 27121323 DOI: 10.18632/Oncotarget.8944 |
0.522 |
|
| 2016 |
Klein EA, Zhang N, Crager M, Maddala T, Febbo PG, Thomas S, Gormley M, Ricci DS, Falzarano SM, Magi-Galluzzi C, Lawrence HJ. A 17-gene genomic prostate score (GPS) as a predictor of biochemical (BCR) and clinical recurrence (CR) in men with surgically treated intermediate- and high-risk prostate cancer (PCa). Journal of Clinical Oncology. 34: 5049-5049. DOI: 10.1200/Jco.2016.34.2_Suppl.104 |
0.448 |
|
| 2016 |
Cooperberg MR, Brand TC, Simko J, Sesterhenn I, Zhang N, Crager M, Maddala T, Lawrence HJ, Febbo PG, Srivastava S, Chan JM, Cullen J, Carroll P. Patient-specific meta-analysis (MA) of two validation studies to predict pathologic outcomes in prostate cancer (PCa) using a 17-gene genomic prostate score (GPS). Journal of Clinical Oncology. 34: 100-100. DOI: 10.1200/Jco.2016.34.2_Suppl.100 |
0.443 |
|
| 2016 |
Lynch JA, Rothney M, Salup R, Ercole CE, Mathur S, Duchene D, Basler JW, Hernandez J, Liss MA, Porter MP, Wright JL, Risk MC, Garzotto M, Efimova O, Kemeter MJ, ... ... Febbo PG, et al. Improving risk stratification among veterans with newly diagnosed, clinically low-risk prostate cancer using the 17-gene genomic prostate score assay. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E16611 |
0.571 |
|
| 2016 |
Bonham M, Nightingale B, Tharayanil A, Denes BS, Rothney M, McCullough D, Bennett J, Febbo PG, Tsiatis AC. Association of PSA and number of cores positive with likelihood of adverse pathology at radical prostatectomy based on a 17-gene expression assay. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E16570 |
0.555 |
|
| 2016 |
Anantharaman A, Nguyen HG, Cooperberg MR, Meng MV, Carroll P, Friedlander TW, Zhang L, Thomas M, Febbo PG, Feng FY, Ryan CJ, Kim W. A pharmacodynamic study of pre-prostatectomy buparlisib in men with high-risk, localized prostate cancer. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E14110 |
0.508 |
|
| 2016 |
Resnick MJ, Lopatin M, Shore ND, Lam PN, Helfand B, Abramson RD, Crager M, Bonham M, Tezcan H, Clark-Langone KM, Silk C, Michelson S, Alexander G, Febbo PG. Abstract 14: Analysis of tumor DNA in urine as a highly sensitive liquid biopsy for patients with non-muscle invasive bladder cancer (NMIBC) Clinical Cancer Research. 22: 14-14. DOI: 10.1158/1557-3265.Pmsclingen15-14 |
0.364 |
|
| 2016 |
Magi-Galluzzi C, Bonham M, Tsiatis A, Falzarano S, Dee A, Maddala T, Knezevic D, Febbo P, Lawrence HJ, Klein E. Mp02-19 Biomarkers Of Biochemical (Bcr) And Clinical Recurrence (Cr) In Prostate Cancer (Pca) Following Radical Prostatectomy (Rp) – Performance Of A 17-Gene Genomic Prostate Score (Gps) And Tests For Pten Loss. The Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1891 |
0.576 |
|
| 2015 |
Dall'Era MA, Maddala T, Polychronopoulos L, Gallagher JR, Febbo PG, Denes BS. Utility of the Oncotype DX Prostate Cancer Assay in Clinical Practice for Treatment Selection in Men Newly Diagnosed with Prostate Cancer: A Retrospective Chart Review Analysis. Urology Practice. 2: 343-348. PMID 37559290 DOI: 10.1016/j.urpr.2015.02.007 |
0.521 |
|
| 2015 |
Badani KK, Kemeter MJ, Febbo PG, Lawrence HJ, Denes BS, Rothney MP, Rothberg MB, Brown GA. The Impact of a Biopsy Based 17-Gene Genomic Prostate Score on Treatment Recommendations in Men with Newly Diagnosed Clinically Prostate Cancer Who are Candidates for Active Surveillance. Urology Practice. 2: 181-189. PMID 37559258 DOI: 10.1016/j.urpr.2014.10.010 |
0.502 |
|
| 2015 |
Brand TC, Zhang N, Crager MR, Maddala T, Dee A, Sesterhenn IA, Simko JP, Cooperberg MR, Srivastava S, Rosner IL, Chan JM, Febbo PG, Carroll PR, Cullen J, Lawrence HJ. Patient-Specific Meta-Analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score. Urology. PMID 26723180 DOI: 10.1016/J.Urology.2015.12.008 |
0.55 |
|
| 2015 |
Pivot X, Mansi L, Chaigneau L, Montcuquet P, Thiery-Vuillemin A, Bazan F, Dobi E, Sautiere JL, Rigenbach F, Algros MP, Butler S, Jamshidian F, Febbo P, Svedman C, Paget-Bailly S, et al. In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy? The Oncologist. 20: 344-50. PMID 25795632 DOI: 10.1634/Theoncologist.2014-0198 |
0.303 |
|
| 2015 |
Cullen J, Rosner IL, Brand TC, Zhang N, Tsiatis AC, Moncur J, Ali A, Chen Y, Knezevic D, Maddala T, Lawrence HJ, Febbo PG, Srivastava S, Sesterhenn IA, McLeod DG. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer. European Urology. 68: 123-31. PMID 25465337 DOI: 10.1016/J.Eururo.2014.11.030 |
0.588 |
|
| 2015 |
Cullen J, Rosner IL, Brand TC, Ali A, Chen Y, Zhang N, Tsiatis AC, Knezevic D, Maddala T, Lawrence HJ, Febbo PG, Srivastava S, Sesterhenn I, Mcleod DG. The association of a 17-gene genomic prostate score with adverse surgical pathology and recurrence following surgery for localized prostate cancer (PCa): A comparison of African American and Caucasian patients. Journal of Clinical Oncology. 33: 86-86. DOI: 10.1200/Jco.2015.33.7_Suppl.86 |
0.551 |
|
| 2015 |
Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg MR, Carroll P. Association between a 17-gene genomic prostate score and multiparametric prostate MRI in men with low- and intermediate-risk prostate cancer (PCa). Journal of Clinical Oncology. 33: 83-83. DOI: 10.1200/Jco.2015.33.7_Suppl.83 |
0.547 |
|
| 2015 |
Knezevic D, Lu R, Burke E, Rothney M, Zhang N, Febbo PG, Lawrence HJ. Evaluation of the contribution of individual gene groups to a 17-gene prognostic prostate cancer signature. Journal of Clinical Oncology. 33: 101-101. DOI: 10.1200/Jco.2015.33.7_Suppl.101 |
0.554 |
|
| 2015 |
Dall'Era MA, Denes B, Lawrence HJ, Tsiatis AC, Rothney M, Maddala T, Febbo PG, Badani K. Clinical utility of a 17-gene genomic prostate score (GPS) for treatment selection in men with newly diagnosed prostate cancer (PCa). Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E16124 |
0.581 |
|
| 2015 |
Dall’Era MA, Maddala T, Polychronopoulos L, Gallagher JR, Febbo PG, Denes BS. Utility of the Oncotype DX® Prostate Cancer Assay in Clinical Practice for Treatment Selection in Men Newly Diagnosed with Prostate Cancer: A Retrospective Chart Review Analysis Urology Practice. 2: 343-348. DOI: 10.1016/J.Urpr.2015.02.007 |
0.57 |
|
| 2015 |
Badani KK, Kemeter MJ, Febbo PG, Lawrence HJ, Denes BS, Rothney MP, Rothberg MB, Brown GA. The Impact of a Biopsy Based 17-Gene Genomic Prostate Score on Treatment Recommendations in Men with Newly Diagnosed Clinically Prostate Cancer Who are Candidates for Active Surveillance Urology Practice. 2: 181-189. DOI: 10.1016/J.Urpr.2014.10.010 |
0.48 |
|
| 2015 |
Leapman M, Westphalen A, Ameli N, Lawrence J, Febbo P, Cooperberg M, Carroll P. MP53-18 ASSOCIATION BETWEEN A 17-GENE GENOMIC PROSTATE SCORE AND MULTI-PARAMETRIC PROSTATE MRI IN MEN WITH LOW AND INTERMEDIATE RISK PROSTATE CANCER (PCA) Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1712 |
0.574 |
|
| 2015 |
Cullen J, Sesterhenn I, Klein E, Mohler J, Carroll P, Cooperberg M, Zhang N, Maddala T, Knezevic D, Tsiatis A, Lawrence HJ, Febbo P. Mp1-05 A Multi-Center Comparison Of A 17-Gene Genomic Prostate Score (Gps) As A Predictor Of Outcomes In African-American (Aa) And Caucasian (Ca) Men With Clinically Localized Prostate Cancer (Pca) The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.168 |
0.524 |
|
| 2015 |
Katz A, Ho A, Burke E, Denes B, Lu R, Rothney M, Bonham M, Tsiatis A, Lawrence J, Febbo P. MP1-01 THE 17-GENE GENOMIC PROSTATE SCORE (GPS) ASSAY: INITIAL CLINICAL EXPERIENCE OF 4,000 PATIENTS Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.164 |
0.504 |
|
| 2014 |
Canfield SE, Kibel AS, Kemeter MJ, Febbo PG, Lawrence HJ, Moul JW. A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer. Reviews in Urology. 16: 172-80. PMID 25548544 |
0.432 |
|
| 2014 |
Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, ... Febbo PG, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. European Urology. 66: 550-60. PMID 24836057 DOI: 10.1016/J.Eururo.2014.05.004 |
0.556 |
|
| 2014 |
Van Allen EM, Foye A, Wagle N, Kim W, Carter SL, McKenna A, Simko JP, Garraway LA, Febbo PG. Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy Prostate Cancer and Prostatic Diseases. 17: 23-27. PMID 24366412 DOI: 10.1038/Pcan.2013.37 |
0.415 |
|
| 2014 |
Liaw BC, Seng SM, Galsky MD, Tsao C, Febbo PG, Oh WK. Biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer. Journal of Clinical Oncology. 32: 170-170. DOI: 10.1200/Jco.2014.32.4_Suppl.170 |
0.496 |
|
| 2014 |
Cullen J, Rosner I, Brand T, Ali A, Chen Y, Zhang N, Tsiatis A, Knezevic D, Maddala T, Lawrence HJ, Febbo P, Srivastava S, Sesterhenn I, McLeod D. Lba22A Prospectively-Designed Study To Determine The Association Of A 17-Gene Genomic Prostate Score With Recurrence Following Surgery For Localised Prostate Cancer (Pca) Annals of Oncology. 25. DOI: 10.1093/Annonc/Mdu438.22 |
0.501 |
|
| 2014 |
Magi-Galluzzi C, Falzarano S, Zhang N, Lawrence HJ, Lee M, Febbo P, Klein E. Mp79-05 An Exploratory Analysis Of The Genomic Prostate Score As A Predictor Of Local Or Metastatic Progression In Men Who Experience Biochemical Recurrence After Surgery For Organ-Confined Prostate Cancer The Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2508 |
0.553 |
|
| 2013 |
Kim W, Febbo PG. The current and future role of sequence-based analysis in prostate cancer treatment. Personalized Medicine. 10: 257-273. PMID 29768744 DOI: 10.2217/Pme.13.13 |
0.579 |
|
| 2013 |
Foye A, Bengtsson H, Kim HJ, Taylor BS, Pourmand N, Febbo PG. Feasibility of RNA sequencing to detect TMPRSS2:ERG fusions following laser capture microdissection of prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 76. PMID 28137101 DOI: 10.1200/Jco.2013.31.6_Suppl.76 |
0.453 |
|
| 2013 |
Spritzer CE, Afonso PD, Vinson EN, Turnbull JD, Morris KK, Foye A, Madden JF, Roy Choudhury K, Febbo PG, George DJ. Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success. Radiology. 269: 816-23. PMID 23925271 DOI: 10.1148/Radiol.13121782 |
0.487 |
|
| 2013 |
Klink JC, Tewari AK, Masko EM, Antonelli J, Febbo PG, Cohen P, Dewhirst MW, Pizzo SV, Freedland SJ. Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways. The Prostate. 73: 754-62. PMID 23192356 DOI: 10.1002/Pros.22619 |
0.411 |
|
| 2013 |
Febbo PG, Goldstein TC, Baertsch R, Youngren J, Newton Y, Bivol A, Small EJ, Stuart JM. Identification of polo-like kinase 1 (PLK1) in aggressive prostate cancer by paradigm analysis. Journal of Clinical Oncology. 31: 5006-5006. DOI: 10.1200/Jco.2013.31.15_Suppl.5006 |
0.428 |
|
| 2013 |
Yu EY, Duan F, Muzi M, Gorelick J, Chin B, Alumkal JJ, Taplin M, Herman B, Higano CS, Doot RK, Hartfeil DM, Febbo PG, Mankoff DA. Correlation of 18F-fluoride PET response to dasatinib in castration-resistant prostate cancer bone metastases with progression-free survival: Preliminary results from ACRIN 6687. Journal of Clinical Oncology. 31: 5003-5003. DOI: 10.1200/Jco.2013.31.15_Suppl.5003 |
0.416 |
|
| 2013 |
Hertz DL, Owzar K, Halabi S, Kelly WK, Zembutsu H, Jiang C, Patel JN, Watson D, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Small EJ, ... Febbo PG, et al. A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance). Journal of Clinical Oncology. 31: 11053-11053. DOI: 10.1200/Jco.2013.31.15_Suppl.11053 |
0.443 |
|
| 2012 |
Harzstark AL, Halabi S, Kelly WK, Morris MJ, Febbo PG, Small EJ. Evaluating the effect of tobacco on prostate cancer outcomes with VEGF-targeted therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 129. PMID 27968183 DOI: 10.1200/Jco.2012.30.5_Suppl.129 |
0.495 |
|
| 2012 |
Tewari AK, Yardimci GG, Shibata Y, Sheffield NC, Song L, Taylor BS, Georgiev SG, Coetzee GA, Ohler U, Furey TS, Crawford GE, Febbo PG. Chromatin accessibility reveals insights into androgen receptor activation and transcriptional specificity. Genome Biology. 13: R88. PMID 23034120 DOI: 10.1186/Gb-2012-13-10-R88 |
0.344 |
|
| 2012 |
Kim MK, Osada T, Barry WT, Yang XY, Freedman JA, Tsamis KA, Datto M, Clary BM, Clay T, Morse MA, Febbo PG, Lyerly HK, Hsu DS. Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer. Molecular Cancer Therapeutics. 11: 1500-9. PMID 22351745 DOI: 10.1158/1535-7163.Mct-11-0937 |
0.396 |
|
| 2012 |
Stewart SB, Bañez LL, Robertson CN, Freedland SJ, Polascik TJ, Xie D, Koontz BF, Vujaskovic Z, Lee WR, Armstrong AJ, Febbo PG, George DJ, Moul JW. Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center. The Journal of Urology. 187: 103-8. PMID 22088334 DOI: 10.1016/J.Juro.2011.09.040 |
0.526 |
|
| 2012 |
Tewari A, Yardimci G, Shibata Y, Sheffield N, Song L, Taylor B, Coetzee G, Furey T, Crawford G, Febbo P. Abstract A12: Chromatin accessibility reveals insight into androgen receptor activation and transcriptional specificity Cancer Research. 72: A12-A12. DOI: 10.1158/1538-7445.Prca2012-A12 |
0.393 |
|
| 2012 |
Tewari AK, Yardimci GG, Crawford GE, Febbo PG. Abstract 2923: Androgen receptor activation changes chromatin structure and transcriptional activation Cancer Research. 72: 2923-2923. DOI: 10.1158/1538-7445.Am2012-2923 |
0.389 |
|
| 2011 |
Oh WK, Galsky MD, Barry M, Fennessey F, Richie JP, Hayes JH, Bhatt RS, Taplin M, Febbo PG, Ross RW. A phase II study of neoadjuvant docetaxel (D) plus bevacizumab (B) in patients (pts) with high-risk localized prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4642. PMID 28023926 DOI: 10.1200/Jco.2011.29.15_Suppl.4642 |
0.502 |
|
| 2011 |
Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 9: S1-32; quiz S33. PMID 22138009 DOI: 10.6004/Jnccn.2011.0137 |
0.41 |
|
| 2011 |
Li W, Balakumaran B, Febbo PG. Abstract C55: Docetaxel resistance mechanisms in prostate cancer: p38 MAPK signaling pathway and microtubule dynamics Cancer Research. 72. DOI: 10.1158/1538-7445.Fbcr11-C55 |
0.491 |
|
| 2010 |
Hsu DS, Kim MK, Balakumaran BS, Acharya CR, Anders CK, Clay T, Lyerly HK, Drake CG, Morse MA, Febbo PG. Immune signatures predict prognosis in localized cancer. Cancer Investigation. 28: 765-73. PMID 20569070 DOI: 10.3109/07357900903095755 |
0.397 |
|
| 2010 |
Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Wang T, Albadine R, Schultz L, Partin AW, Jimeno A, Fedor H, Febbo PG, et al. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3057-66. PMID 20501622 DOI: 10.1158/1078-0432.Ccr-10-0124 |
0.525 |
|
| 2010 |
Balakumaran BS, Herbert JT, Febbo PG. MYC activity mitigates response to rapamycin in prostate cancer through 4EBP1-mediated inhibition of autophagy. Autophagy. 6: 281-2. PMID 20026909 DOI: 10.4161/Auto.6.2.10921 |
0.376 |
|
| 2010 |
Foye A, Febbo PG. Cancer gene profiling in prostate cancer. Methods in Molecular Biology (Clifton, N.J.). 576: 293-326. PMID 19882268 DOI: 10.1007/978-1-59745-545-9_15 |
0.578 |
|
| 2010 |
Hsu DS, Balakumaran BS, Acharya CR, Vlahovic V, Walters KS, Garman K, Anders C, Riedel RF, Lancaster J, Harpole D, Dressman HK, Nevins JR, Febbo PG, Potti A. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer (Journal of Clinical Oncology (2007) 25, (4350-4357)) Journal of Clinical Oncology. 28: 5229. DOI: 10.1200/Jco.2010.33.7311 |
0.352 |
|
| 2010 |
VanDeusen JB, Osada T, Morse M, Clary BM, Lyerly HK, Nevins JR, Clay TM, Febbo PG, Hsu SD. Use of gene expression signatures to predict in vivo sensitivity of human metastatic colorectal cancer to chemotherapy and to identify novel drug combinations. Journal of Clinical Oncology. 28: e14064-e14064. DOI: 10.1200/Jco.2010.28.15_Suppl.E14064 |
0.373 |
|
| 2010 |
Hsu SD, Kim MK, Foye A, Silvestri A, Lyerly HK, Morse M, Petricoin E, Febbo PG. Use of gene expression signatures to identify origin of primary and therapeutic strategies for patients with advanced solid tumors. Journal of Clinical Oncology. 28: 10504-10504. DOI: 10.1200/Jco.2010.28.15_Suppl.10504 |
0.317 |
|
| 2010 |
Antonelli J, Jones L, Thomas J, Masko E, Lloyd J, Poulton S, Phillips T, Tewari A, Febbo P, Pollak M, Dewhirst M, Freedland SJ. 89 Effect Of Voluntary Wheel Running On Growth Of Prostate Cancer In Immunocompromised And Immunocompetent Mouse Models The Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.138 |
0.524 |
|
| 2009 |
Oh WK, Febbo PG, Richie JP, Fennessy FM, Scibelli G, Hayes JH, Choueiri TK, Tempany CM, Taplin ME, Ross RW. A phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients (pts) with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5060. PMID 27962979 DOI: 10.1200/Jco.2009.27.15_Suppl.5060 |
0.535 |
|
| 2009 |
Balakumaran BS, Porrello A, Hsu DS, Glover W, Foye A, Leung JY, Sullivan BA, Hahn WC, Loda M, Febbo PG. MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Cancer Research. 69: 7803-10. PMID 19773438 DOI: 10.1158/0008-5472.Can-09-0910 |
0.54 |
|
| 2009 |
Armstrong AJ, Febbo PG. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. The Oncologist. 14: 816-27. PMID 19684076 DOI: 10.1634/Theoncologist.2009-0043 |
0.543 |
|
| 2009 |
Febbo PG. Genomic approaches to outcome prediction in prostate cancer. Cancer. 115: 3046-57. PMID 19544546 DOI: 10.1002/Cncr.24350 |
0.592 |
|
| 2009 |
Febbo PG. Epigenetic events highlight the challenge of validating prognostic biomarkers during the clinical and biologic evolution of prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3088-90. PMID 19470924 DOI: 10.1200/Jco.2008.20.9783 |
0.556 |
|
| 2009 |
Mavropoulos JC, Buschemeyer WC, Tewari AK, Rokhfeld D, Pollak M, Zhao Y, Febbo PG, Cohen P, Hwang D, Devi G, Demark-Wahnefried W, Westman EC, Peterson BL, Pizzo SV, Freedland SJ. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prevention Research (Philadelphia, Pa.). 2: 557-65. PMID 19470786 DOI: 10.1158/1940-6207.Capr-08-0188 |
0.375 |
|
| 2009 |
Loda M, Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, et al. Fatty acid synthase: A metabolic enzyme and candidate oncogene in prostate cancer Journal of the National Cancer Institute. 101: 519-532. PMID 19318631 DOI: 10.1093/Jnci/Djp030 |
0.516 |
|
| 2009 |
Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT, Nelson PS, Febbo PG. Genomic strategy for targeting therapy in castration-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2022-9. PMID 19289629 DOI: 10.1200/Jco.2008.17.2882 |
0.571 |
|
| 2009 |
Balakumaran BS, Herbert JT, Glover W, Foye A, Pierobon M, Petricoin E, George D, Febbo PG. Abstract C61: The PI3K pathway inhibition in prostate cancer cells is enhanced by dual targeting with the mTOR inhibitor RAD001 and a mTOR/PI3K inhibitor leading to decreased cell proliferation and increased autophagy Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C61 |
0.515 |
|
| 2009 |
Tewari AK, Song L, Furey TS, Crawford GE, Febbo PG. Abstract B44: Chromatin structure impacts androgen receptor transcriptional specificity in prostate cancer cell lines Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-B44 |
0.484 |
|
| 2009 |
Klink JC, Poulton S, Antonelli J, Potter MQ, Jayachandran J, Tewari AK, Febbo PG, Pizzo SV, Freedland SJ. RESVERATROL ALTERS PROSTATE CANCER XENOGRAFT GROWTH Journal of Urology. 181: 259-259. DOI: 10.1016/S0022-5347(09)60738-2 |
0.496 |
|
| 2009 |
Freedland SJ, Mavropoulos JC, Buschemeyer WC, Tewari AK, Rokhfeld D, Pollak M, Zhao Y, Febbo PG, Cohen P, Hwang D, Devi G, Demark-Wahnefried W, Westman EC, Peterson BL, Pizzo SV. A NO CARBOHYDRATE DIET SIGNIFICANTLY PROLONGS SURVIVAL IN A PROSTATE CANCER XENOGRAFT MODEL VIA IGF-1 AND GLOBAL GENE EXPRESSION CHANGES Journal of Urology. 181: 47-47. DOI: 10.1016/S0022-5347(09)60144-0 |
0.525 |
|
| 2009 |
Febbo PG, Kantoff PW. CHAPTER 74 – Prostate Cancer Genomic and Personalized Medicinevolumes I & Ii. 898-912. DOI: 10.1016/B978-0-12-369420-1.00074-3 |
0.555 |
|
| 2008 |
Mendiratta P, Tewari A, Guinney J, Porrello A, Barry WT, Febbo PG. A genomic strategy for targeting therapy in castration-Independent Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5067. PMID 27948753 DOI: 10.1200/Jco.2008.26.15_Suppl.5067 |
0.528 |
|
| 2008 |
Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ, Mortimer J, Reckamp K, et al. NCCN Task Force Report: mTOR inhibition in solid tumors. Journal of the National Comprehensive Cancer Network : Jnccn. 6: S1-20; quiz S21-2. PMID 18926092 DOI: 10.6004/Jnccn.2008.2005 |
0.355 |
|
| 2008 |
Riedel RF, Porrello A, Pontzer E, Chenette EJ, Hsu DS, Balakumaran B, Potti A, Nevins J, Febbo PG. A genomic approach to identify molecular pathways associated with chemotherapy resistance. Molecular Cancer Therapeutics. 7: 3141-9. PMID 18852117 DOI: 10.1158/1535-7163.Mct-08-0642 |
0.35 |
|
| 2008 |
Fall K, Stark JR, Mucci LA, Chan J, Stampfer MJ, Kurth T, Febbo PG, Kantoff P, Ma J. No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk. The Prostate. 68: 1416-20. PMID 18615538 DOI: 10.1002/Pros.20797 |
0.449 |
|
| 2008 |
Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3324-30. PMID 18612148 DOI: 10.1200/Jco.2007.14.2471 |
0.32 |
|
| 2008 |
Oltean S, Febbo PG, Garcia-Blanco MA. Dunning rat prostate adenocarcinomas and alternative splicing reporters: powerful tools to study epithelial plasticity in prostate tumors in vivo. Clinical & Experimental Metastasis. 25: 611-9. PMID 18523850 DOI: 10.1007/S10585-008-9186-Y |
0.474 |
|
| 2008 |
Augustine CK, Yoshimoto Y, Gupta M, Zipfel PA, Selim MA, Febbo P, Pendergast AM, Peters WP, Tyler DS. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Research. 68: 3777-84. PMID 18483261 DOI: 10.1158/0008-5472.Can-07-5949 |
0.304 |
|
| 2008 |
Edelman EJ, Guinney J, Chi JT, Febbo PG, Mukherjee S. Modeling cancer progression via pathway dependencies. Plos Computational Biology. 4: e28. PMID 18282083 DOI: 10.1371/Journal.Pcbi.0040028 |
0.483 |
|
| 2008 |
Riedel RF, Friedman D, Febbo PG. A genomic approach to identify therapeutic targets in histologic subtypes of soft tissue sarcoma Journal of Clinical Oncology. 26: 10577-10577. DOI: 10.1200/Jco.2008.26.15_Suppl.10577 |
0.301 |
|
| 2008 |
Tewari A, Guinney J, Febbo PG. ANDROGEN RECEPTOR (AR) ACTIVITY SIGNATURES TO OPTIMIZE SYSTEMIC THERAPY IN ADVANCED PROSTATE CANCER (CaP) Journal of Urology. 179: 254-254. DOI: 10.1016/S0022-5347(08)60734-X |
0.496 |
|
| 2007 |
Mendiratta P, Febbo PG. Genomic signatures associated with the development, progression, and outcome of prostate cancer. Molecular Diagnosis & Therapy. 11: 345-54. PMID 18078352 DOI: 10.1007/Bf03256258 |
0.587 |
|
| 2007 |
Hsu DS, Balakumaran BS, Acharya CR, Vlahovic V, Walters KS, Garman K, Anders C, Riedel RF, Lancaster J, Harpole D, Dressman HK, Nevins JR, Febbo PG, Potti A. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 4350-7. PMID 17906199 DOI: 10.1200/Jco.2007.11.0593 |
0.347 |
|
| 2007 |
Li W, Wu CL, Febbo PG, Olumi AF. Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. The American Journal of Pathology. 171: 1189-98. PMID 17702894 DOI: 10.2353/Ajpath.2007.070285 |
0.476 |
|
| 2007 |
Acharya C, Hsu D, Balakumaran B, Walters K, Vlahovic V, Riedel R, Garst J, Febbo P, Nevins J, Potti A. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced non- small cell lung cancer (NSCLC) Journal of Clinical Oncology. 25: 7501-7501. DOI: 10.1200/Jco.2007.25.18_Suppl.7501 |
0.363 |
|
| 2007 |
Riedel RF, Porrello A, Chenette E, Potti A, Nevins JR, Febbo PG. A genomic approach to identify mechanisms associated with chemotherapy resistance Journal of Clinical Oncology. 25: 2534-2534. DOI: 10.1200/Jco.2007.25.18_Suppl.2534 |
0.355 |
|
| 2007 |
Hsu SD, Anders CK, Acharya CR, Zhang Y, Wang Y, Foekens JA, Blackwell KL, Drake CG, Morse MA, Febbo PG. Immune signatures hold prognostic import across solids tumors Journal of Clinical Oncology. 25: 21041-21041. DOI: 10.1200/Jco.2007.25.18_Suppl.21041 |
0.353 |
|
| 2007 |
Polascik TJ, Mouraviev V, Mayes JM, Sun L, Madden J, George D, Febbo P, Maul JW. 1776: Prostate Cancer Laterality as a Rationale for the Clinical Application of Focal Ablative Therapy: an Analysis of 1184 Prostatectomy Specimens The Journal of Urology. 177: 590-590. DOI: 10.1016/S0022-5347(18)31964-5 |
0.544 |
|
| 2006 |
Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H, Kelley MJ, Petersen R, Harpole D, Marks J, Berchuck A, Ginsburg GS, Febbo P, et al. Genomic signatures to guide the use of chemotherapeutics. Nature Medicine. 12: 1294-300. PMID 17057710 DOI: 10.1038/Nm1491 |
0.329 |
|
| 2006 |
Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, Ogino S, Farsetti A, Porrello A, Finn S, Zimmermann J, Febbo P, Loda M. The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Research. 66: 8625-32. PMID 16951176 DOI: 10.1158/0008-5472.Can-06-1374 |
0.521 |
|
| 2006 |
Anscher MS, Clough R, Robertson CN, Prosnitz LR, Dahm P, Walther P, Donatucci CF, Albala DM, Febbo P, George DJ, Sun L, Moul JW. Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. Prostate Cancer and Prostatic Diseases. 9: 254-260. PMID 16880828 DOI: 10.1038/Sj.Pcan.4500903 |
0.529 |
|
| 2006 |
Edelman E, Porrello A, Guinney J, Balakumaran B, Bild A, Febbo PG, Mukherjee S. Analysis of sample set enrichment scores: assaying the enrichment of sets of genes for individual samples in genome-wide expression profiles. Bioinformatics (Oxford, England). 22: e108-16. PMID 16873460 DOI: 10.1093/Bioinformatics/Btl231 |
0.368 |
|
| 2006 |
Balakumaran BS, Febbo PG. New insights into prostate cancer biology. Hematology/Oncology Clinics of North America. 20: 773-96. PMID 16861114 DOI: 10.1016/J.Hoc.2006.06.005 |
0.577 |
|
| 2006 |
Febbo PG, Kantoff PW. Noise and bias in microarray analysis of tumor specimens. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3719-21. PMID 16822841 DOI: 10.1200/Jco.2006.06.7942 |
0.39 |
|
| 2006 |
Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, Kutok J, Aster JC, Tang J, Kuefer R, Hofer MD, Febbo PG, Chinnaiyan AM, Rubin MA. Defining aggressive prostate cancer using a 12-gene model. Neoplasia (New York, N.Y.). 8: 59-68. PMID 16533427 DOI: 10.1593/Neo.05664 |
0.587 |
|
| 2006 |
Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Research. 66: 2815-25. PMID 16510604 DOI: 10.1158/0008-5472.Can-05-4000 |
0.578 |
|
| 2006 |
Febbo PG, Thorner A, Rubin MA, Loda M, Kantoff PW, Oh WK, Golub T, George D. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 152-8. PMID 16397037 DOI: 10.1158/1078-0432.Ccr-05-1652 |
0.512 |
|
| 2006 |
Potti A, Dressman HK, Bild A, Riedel R, Kelley M, Ginsburg G, Lancaster J, Nevins J, Febbo P. A genomic strategy to combinatorial therapeutics in solid tumors Journal of Clinical Oncology. 24: 2031-2031. DOI: 10.1200/Jco.2006.24.18_Suppl.2031 |
0.397 |
|
| 2006 |
Priolo C, Tang D, Brahmandam M, Benassi B, Sicinska E, Ogino S, Farsetti A, Porrello A, Febbo PG, Zimmermann J, Loda MF. USP2a is an oncogenic isopeptidase and a potential target in prostate cancer Journal of Clinical Oncology. 24: 14522-14522. DOI: 10.1200/Jco.2006.24.18_Suppl.14522 |
0.435 |
|
| 2005 |
Febbo PG, Ginsburg GS. Personalized diagnostic and therapeutic strategies in oncology Personalized Medicine. 2: 97-110. PMID 29788586 DOI: 10.1517/17410541.2.2.97 |
0.401 |
|
| 2005 |
Elliston KO, Pratt D, Hahn W, Febbo P. Identification of the androgen-induced transcriptional program of human prostate cancer revealed by causal analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4637. PMID 27947009 DOI: 10.1200/Jco.2005.23.16_Suppl.4637 |
0.54 |
|
| 2005 |
Riedel RF, Febbo PG. Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer. Future Oncology (London, England). 1: 461-6. PMID 16556022 DOI: 10.2217/14796694.1.4.461 |
0.331 |
|
| 2005 |
Bild A, Febbo PG. Application of a priori established gene sets to discover biologically important differential expression in microarray data Proceedings of the National Academy of Sciences of the United States of America. 102: 15278-15279. PMID 16230612 DOI: 10.1073/Pnas.0507477102 |
0.459 |
|
| 2005 |
Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5233-40. PMID 16033841 DOI: 10.1158/1078-0432.Ccr-05-0299 |
0.556 |
|
| 2005 |
Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A, Frank DA. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Research. 65: 5054-62. PMID 15958548 DOI: 10.1158/0008-5472.Can-04-4281 |
0.356 |
|
| 2005 |
Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, Nevins JR, Marks JR. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 3686-96. PMID 15897565 DOI: 10.1158/1078-0432.Ccr-04-2398 |
0.364 |
|
| 2005 |
Febbo PG, Lowenberg M, Thorner AR, Brown M, Loda M, Golub TR. Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. The Journal of Urology. 173: 1772-7. PMID 15821585 DOI: 10.1097/01.Ju.0000155845.44729.Ba |
0.548 |
|
| 2005 |
Paris PL, Andaya A, Fridlyand J, Jain A, Weinberg V, Kowbel D, Brebner J, Simko J, Volik S, Albertson D, Pinkel D, Febbo P, Chinnaiyan AM, Pienta K, Rubin MA, et al. 387: Whole Genome Scanning Identifies Genotypes Associated with Recurrence and Metastasis in Prostate Tumors The Journal of Urology. 173: 106-106. DOI: 10.1016/S0022-5347(18)34640-8 |
0.481 |
|
| 2004 |
Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, Signoretti S, Campbell KT, Sellers WR, Roberts TM, Loda M, Golub TR, Hahn WC. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Research. 64: 8867-75. PMID 15604246 DOI: 10.1158/0008-5472.Can-04-2938 |
0.555 |
|
| 2004 |
Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Medicine. 10: 594-601. PMID 15156201 DOI: 10.1038/Nm1052 |
0.457 |
|
| 2004 |
Tay MH, Kaufman DS, Regan MM, Leibowitz SB, George DJ, Febbo PG, Manola J, Smith MR, Kaplan ID, Kantoff PW, Oh WK. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 15: 974-8. PMID 15151957 DOI: 10.1093/Annonc/Mdh221 |
0.528 |
|
| 2004 |
Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson JE, Volik S, Albertson DG, Pinkel D, Alers JC, van der Kwast TH, Vissers KJ, ... ... Febbo PG, et al. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Human Molecular Genetics. 13: 1303-13. PMID 15138198 DOI: 10.1093/Hmg/Ddh155 |
0.507 |
|
| 2004 |
Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Molecular Cancer Research : McR. 1: 707-15. PMID 12939396 |
0.437 |
|
| 2004 |
Tay MH, George DJ, Gilligan TD, Kelly SM, Appleby L, Taplin M-, Febbo PG, Kantoff PW, Oh WK. Docetaxel plus carboplatin (DC) may have significant activity in hormone refractory prostate cancer (HRPC) patients who have progressed after prior docetaxel-based chemotherapy Journal of Clinical Oncology. 22: 4679-4679. DOI: 10.1200/Jco.2004.22.90140.4679 |
0.498 |
|
| 2003 |
Febbo PG, Sellers WR. Use of expression analysis to predict outcome after radical prostatectomy. The Journal of Urology. 170: S11-9; discussion S1. PMID 14610405 DOI: 10.1097/01.Ju.0000095567.03807.A1 |
0.472 |
|
| 2003 |
Lieberfarb ME, Lin M, Lechpammer M, Li C, Tanenbaum DM, Febbo PG, Wright RL, Shim J, Kantoff PW, Loda M, Meyerson M, Sellers WR. Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Research. 63: 4781-5. PMID 12941794 |
0.411 |
|
| 2003 |
Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q, Bikoff R, Ma H, Kantoff PW, Golub TR, Loda M, Sellers WR. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proceedings of the National Academy of Sciences of the United States of America. 100: 7841-6. PMID 12799464 DOI: 10.1073/Pnas.1232229100 |
0.545 |
|
| 2002 |
Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 1: 203-9. PMID 12086878 DOI: 10.1016/S1535-6108(02)00030-2 |
0.572 |
|
| 2000 |
Farmer DA, Platz EA, Febbo PG, Stampfer MJ, Kantoff PW, Giovannucci E. HRAS1 proto-oncogene polymorphism and prostate cancer Prostate Journal. 2: 211-218. DOI: 10.1046/J.1525-1411.2000.24010.X |
0.522 |
|
| Show low-probability matches. |